|
Kartagener Syndrome
|
0.510 |
GermlineCausalMutation
|
disease |
ORPHANET |
De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry.
|
31630787 |
2019 |
|
Kartagener Syndrome
|
0.510 |
Biomarker
|
disease |
BEFREE |
The human FOXJ1 gene which maps to chromosome 17q, is thus an excellent candidate gene for Kartagener Syndrome (KS), a subphenotype of Primary Ciliary Dyskinesia (PCD), characterized by bronchiectasis, chronic sinusitis and situs inversus.
|
11060460 |
2000 |
|
Kartagener Syndrome
|
0.510 |
Biomarker
|
disease |
MGD |
|
|
|
|
Primary Ciliary Dyskinesia
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
However, it is plausible that IIP transcriptionally regulated by FOXJ1 and/or differentially expressed in PCD are likely to have crucial roles in motile cilia.
|
30881373 |
2019 |
|
Primary Ciliary Dyskinesia
|
0.320 |
GermlineCausalMutation
|
disease |
ORPHANET |
De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry.
|
31630787 |
2019 |
|
Primary Ciliary Dyskinesia
|
0.320 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that the FOXJ1 gene is not responsible for the PCD/KS phenotype in the families examined.
|
11060460 |
2000 |
|
Polynesian Bronchiectasis
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry.
|
31630787 |
2019 |
|
Ciliary Dyskinesia, Primary, 1, With Or Without Situs Inversus
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry.
|
31630787 |
2019 |
|
Ciliary Motility Disorders
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Our findings provide clues regarding the role of FOXJ1 as a tumor inducer in bladder cancer and an enhancer in glycolysis.
|
29129693 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Taken together, the present findings demonstrated that miR-6852 exerted a tumor suppressive role through targeting FOXJ1 in GC.
|
30214548 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We concluded that FOXJ1 was expressed in low quantities in bladder epithelial carcinoma, which was closely correlated with the biological characteristics of the tumor.
|
29434839 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
RESULTS Increased expression of FOXJ1was significantly associated with clinical stage (p<0.05), metastasis of lymph node (p<0.05), and invasion depth (p<0.001) in colon cancer, suggesting FOXJ1 is a tumor promoter in CRC.
|
28209947 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
All samples were evaluated by immunohistochemistry for expression of CRX, a master transcriptional regulator of photoreceptor differentiation expressed in pineal gland and retina and/or FOXJ1, a master transcriptional regulator of ciliogenesis expressed in normal ependymal cells and ependymal neoplasms.
|
28719464 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Expression of FOXJ1 and its transcriptional programme is maintained in many well-differentiated human tumours that arise along the ventricle, including low-grade ependymal tumours and choroid plexus papillomas.
|
26690880 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Multivariate analysis indicated that tumor grade (P < 0.0001), metastasis (P = 0.0451), tumor size (P = 0.0459), FOXJ1 (P = 0.0011), and Ki-67 (P = 0.0006) were independent prognostic markers for HCC.
|
22488567 |
2013 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Therefore, deregulated Foxj1 is supposed to be associated with autoimmune diseases and/or other inflammatory diseases.
|
18160851 |
2007 |
|
Autoimmune Diseases
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Thus, dysregulation of FOXJ1 is thought to be associated with autoimmune diseases and/or other inflammatory diseases.
|
16518568 |
2006 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Cutting edge: Foxj1 protects against autoimmunity and inhibits thymocyte egress.
|
16339515 |
2005 |
|
Autoimmune Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, Foxj1 likely modulates inflammatory reactions and prevents autoimmunity by antagonizing proinflammatory transcriptional activities.
|
14963332 |
2004 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Transwell assay revealed that FOXJ1-siRNA-transfected cells showed significant reduction in cell migration and invasion compared to the cells transfected with control siRNA.
|
31062413 |
2019 |
|
Allergic rhinitis (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Elevated FOXJ1 localization scores and down-regulation of <i>FOXJ1</i> mRNA levels were observed in NPs with co-existing AR or asthma (all <i>P </i>< 0.05).
|
30459817 |
2018 |
|
Allergic rhinitis (disorder)
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We sought to investigate the expression and localization of FOXJ1 in inferior turbinate from patients with AR and controls.
|
29635245 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
RESULTS Increased expression of FOXJ1was significantly associated with clinical stage (p<0.05), metastasis of lymph node (p<0.05), and invasion depth (p<0.001) in colon cancer, suggesting FOXJ1 is a tumor promoter in CRC.
|
28209947 |
2017 |